What is a stock summary page? Click here for an overview.
Business Description
ImmunityBio Inc
NAICS : 541714
SIC : 8731
ISIN : US45256X1037
Share Class Description:
IBRX: Ordinary SharesCompare
Compare
Traded in other countries / regions
IBRX.USA26CA.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2021-03-10Description
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.3 | |||||
| Equity-to-Asset | -1.28 | |||||
| Debt-to-Equity | -1.03 | |||||
| Debt-to-EBITDA | -1.91 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -12.65 | |||||
| Beneish M-Score | 15.92 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 119 | |||||
| 3-Year EBITDA Growth Rate | 22.9 | |||||
| 3-Year EPS without NRI Growth Rate | 8.5 | |||||
| 3-Year FCF Growth Rate | 10.5 | |||||
| 3-Year Book Growth Rate | 2 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 251.73 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 48.82 | |||||
| 9-Day RSI | 50.08 | |||||
| 14-Day RSI | 49.44 | |||||
| 3-1 Month Momentum % | 7.47 | |||||
| 6-1 Month Momentum % | -11.95 | |||||
| 12-1 Month Momentum % | -46.26 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.36 | |||||
| Quick Ratio | 3.21 | |||||
| Cash Ratio | 2.73 | |||||
| Days Sales Outstanding | 62.45 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -28.9 | |||||
| Shareholder Yield % | -1.34 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -2334.23 | |||||
| Net Margin % | -2804.77 | |||||
| FCF Margin % | -2700.06 | |||||
| ROA % | -98.61 | |||||
| ROIC % | -153.12 | |||||
| 3-Year ROIIC % | 6 | |||||
| ROC (Joel Greenblatt) % | -159.89 | |||||
| ROCE % | -78.03 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 134.77 | |||||
| EV-to-EBIT | -10.25 | |||||
| EV-to-Forward-EBIT | -11.91 | |||||
| EV-to-EBITDA | -10.93 | |||||
| EV-to-Revenue | 196 | |||||
| EV-to-Forward-Revenue | 28.34 | |||||
| EV-to-FCF | -7.26 | |||||
| Price-to-GF-Value | 0.05 | |||||
| Earnings Yield (Greenblatt) % | -9.76 | |||||
| FCF Yield % | -16.48 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IBRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ImmunityBio Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 14.745 | ||
| EPS (TTM) ($) | -0.61 | ||
| Beta | 0.29 | ||
| 3-Year Sharpe Ratio | 0.18 | ||
| 3-Year Sortino Ratio | 0.31 | ||
| Volatility % | 99.18 | ||
| 14-Day RSI | 49.44 | ||
| 14-Day ATR ($) | 0.255178 | ||
| 20-Day SMA ($) | 2.9085 | ||
| 12-1 Month Momentum % | -46.26 | ||
| 52-Week Range ($) | 2.28 - 10.53 | ||
| Shares Outstanding (Mil) | 853.44 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ImmunityBio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ImmunityBio Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
ImmunityBio Inc Frequently Asked Questions
What is ImmunityBio Inc(IBRX)'s stock price today?
The current price of IBRX is $2.84. The 52 week high of IBRX is $10.53 and 52 week low is $2.28.
When is next earnings date of ImmunityBio Inc(IBRX)?
The next earnings date of ImmunityBio Inc(IBRX) is 2025-05-09 Est..
Does ImmunityBio Inc(IBRX) pay dividends? If so, how much?
ImmunityBio Inc(IBRX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers